SEA-CD70

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
140 patients (estimated)
Sponsors
Seagen Inc.
Tags
Monoclonal Antibody
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
1990
NCT Identifier
NCT04227847

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.